Global Biologics Market, Industry and R&D: Forecasts 2015-2025 : Challenges and Opportunities from Rising Drug Demand and Biosimilar Competition

生物製剤の世界市場:蛋白質療法、単クローン抗体、融合蛋白、再生医療、ワクチン

◆タイトル:Global Biologics Market, Industry and R&D: Forecasts 2015-2025 : Challenges and Opportunities from Rising Drug Demand and Biosimilar Competition
◆商品コード:VGAIN5081915
◆調査・発行会社:visiongain
◆発行日:2015年8月
◆ページ数:233
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、生物製剤の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・生物製剤の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・生物製剤の世界市場:セグメント別市場分析
 (蛋白質療法、単クローン抗体、融合蛋白、再生医療)
・地域別市場分析、市場規模予測
・市場環境分析
・主要企業分析
・結論

Biological Therapies – Discover Revenue Prospects Now, Benefiting Your Authority
Do you want to assess how high biological drug sales can go? Visiongain’s new analysis gives you those revenue forecasts to 2025 at overall world market, therapeutic class and national level. For biologics you discover data, opportunities, R&D and sales potentials.

Our updated report gives you multilevel revenue predictions for biotechnological drugs from 2015, helping you stay ahead. You also investigate trends, results, technologies and expected products, benefiting your reputation for technological and commercial insight.

With our study you also assess the influence of biosimilars and other emerging treatments on that lucrative, expanding pharma industry and market.

Read on, then, to explore the biologics market from 2015, also seeing predicted revenue.

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, business results, sales growth rates and market shares. There you explore quantitative and qualitative analyses, assessing sales potentials and R&D. You gain 57 tables and 33 charts, with original research and analysis.

That way you assess clinical, technological and commercial trends, results and potentials such as these issues:
• Why will the biologics market achieve revenue growth from 2015 to 2025, and what sales are possible from existing drugs and R&D?
• When will that industry achieve worldwide revenues over $300bn?
• What treatment classes give the most promise for developers, producers and sellers?
• Who are the best-placed companies in the biopharma industry?
• Where are the most important and promising regions for selling those treatments?
• How will biological drug producers serve regulators, doctors, patients and payers?

Opportunities in biologics to benefit drug developers, producers and marketers
In 2014 seven of the top ten best-selling drugs were biologics. Many opportunities remain for products based on proteins and related biopharma technologies. Our study lets you discover what segments are most likely to prosper, from 2015 to 2025, through forecasted sales.

Why struggle to find data and other information, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations now. With visiongain’s new investigation see how you can save time and benefit your reputation for commercial insight.

Although no single study covers everything, the following sections show how our new investigation benefits your work.

Predictions for that world market and submarkets – see what sales growth is possible
Along with revenue prediction for the overall world market for biologics, our study shows forecasts from 2015 to 2025 for 13 individual submarkets:
• Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
• Vaccines.

Our report gives sales potentials of those biopharmaceuticals. See there how you can benefit your plans, decisions, presentations and proposals, also helping your influence.

That new investigation also discusses what stimulates and restrains sales of biologics. You explore that industry, seeing what products can achieve the most success. Discover, from 2015, how pharmaceutical companies can gain from biologics.

Our study also divides its overall world forecast into geographical segments.

National markets for therapeutic proteins – where will highest sales and growth occur?
Our study predicts rising demand for biological drugs in developed and developing countries. Discover what sales results and expansion are possible from 2015.

The analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

In our study you discover outlooks for improving treatment coverage and expanding revenues. You assess the biologic industry’s future – needs, developments, demands and opportunities.

Our work explores issues affecting biopharma companies, influencing their results.

【レポートの目次】

1. Report Overview
1.1 Biologics Overview
1.2 Why you Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to the Biologics Market and Key Concepts
2.1 Biologics: Large and Complex Products
2.2 A Brief History of Biological Drug Development
2.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
2.4 What are Biosimilars?
2.4.1 Brief History of Biosimilars
2.4.2 What are Interchangeable Biological Products and how do they Differ from Biosimilars?
2.4.3 Prescription of Interchangeables vs Biosimilars and how this sets the FDA apart from the EMA
2.4.4 What Share of the Overall Biologics Market do they Currently Hold?
2.5 What are Next-Generation Biologics / Biobetters? What Share of the Overall Biologics Market do they Currently Hold?
2.6 Marginal Cases
2.7 Vaccines Market

3. The Global Biologics Market, 2015-2025
3.1 Global Biologics Market Forecast, 2015-2025
3.2 What Factors Will Drive Growth in the Biologics Market?
3.3 Ageing Population and the Rise of Chronic Disease
3.4 Seven of the Top Ten Best-Selling Drugs are Biologics
3.5 Biologics Constitute 19% of the Global Pharmaceutical Market – Further Launches will Drive Market
3.6 Biosimilars – Both an Opportunity and a Threat
3.7 What Factors will Restrain Growth in the Biologics Market?
3.8 High Costs in the Face of Declining National Healthcare Budgets
3.9 In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
3.10 Over $67bn worth of Biologic Patents due to Expire by 2020
3.11 Administration is often not as Convenient as that for Conventional Drugs
3.12 Biologics Market: Submarket Forecasts, 2015-2025

4. Protein Therapeutics Submarket, 2015-2025
4.1 Largest and Most Diverse Submarket
4.2 Proteins have been used Medicinally since the 19th Century
4.2.1 Recombinant DNA Technology – The Major Breakthrough in the use of Protein Drugs
4.3 Protein Therapeutics Submarket Forecast, 2015-2025
4.4 Insulin Submarket, 2015-2025
4.4.1 The First Protein Therapeutic
4.4.2 430 Million People Expected to be Diagnosed with Diabetes by 2030
4.4.3 Novo Nordisk, Sanofi and Eli Lilly Dominate the Insulin Segment
4.4.3.1 Sanofi: Releases Long-Acting Version of Lantus, as Patents for that Drug Expires
4.4.3.2 Eli Lilly: Portfolio Includes Human Insulin and Analogues
4.4.3.3 Novo Nordisk: Leader in Human Insulin Production
4.4.4 Duration of Action is the Major Differentiator for Insulins
4.4.5 New Approvals in the Insulin Market
4.4.5.1 Long-Awaited US Approval of Tresiba Could Come in October this Year
4.4.5.2 IDegLira / Xultrophy – Another Way to Sell Tresiba in the EU, Superior Results to Lantus in Phase 3
4.4.5.3 Toujeo – Sanofi’s Successor to Lantus, Already Launched in the US and Has Received Approval in Europe
4.4.6 Insulin Pipeline
4.4.6.1 BIL / LY2605541 (Eli Lilly) – Holds Promise, What Will More Testing Bring?
4.4.6.2 FIAsp / NN1218 – Novo Nordisk’s Late Stage Faster-Acting Insulin Aspart
4.4.7 Biosimilar Insulin
4.4.7.1 Approved Insulin Biosimilars
4.4.7.2 Abasaglar / Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets
4.4.7.3 Insulin Glargine is the Main Biosimilar Target
4.4.8 Insulin Submarket Forecast, 2015-2025
4.5 Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone
4.5.1 Erythropoietin
4.5.1.1 First-Generation Therapies Launched in the 1980s
4.5.1.2 Three Products Lead the Market
4.5.1.3 Mircera (Roche) Provides Competition for Market Leader Amgen
4.5.1.4 Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand
4.5.1.5 The Challenge from Oral Therapies is Coming
4.5.1.6 Treating Anaemia in Patients with CKD – The Leading Use of EPO Therapies
4.5.1.7 Many Biosimilar Epoetins Approved Around the World
4.5.2 G-CSF
4.5.2.1 G-CSF: Discovered 1983. Recombinant Forms Available Since 1991
4.5.2.2 Amgen Leads the Market
4.5.2.3 Teva Aiming to Challenge Amgen’s Dominance
4.5.2.4 Facing Much Biosimilar Competition Around the World
4.5.3 Human Growth Hormone
4.5.3.1 Human Growth Hormone: First Extracted in 1958
4.5.3.2 Novo Nordisk Dominates Market
4.5.3.3 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
4.5.3.4 Multiple Biosimilars Available – Omnitrope (Sandoz) is Market Leader
4.5.4 Other Recombinant Hormones Submarket Forecast, 2015-2025
4.6 Plasma and Recombinant Coagulating Factors
4.6.1 Discovery of Plasma and Clotting Proteins
4.6.2 Types of Recombinant Factor
4.6.3 Clotting Factor Deficiency Diseases
4.6.4 Baxter: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products
4.6.4.1 Baxter: New Product Launches Include Rixubis and Obizur
4.6.5 Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market
4.6.5.1 Novo Nordisk: Developing Long-Acting Therapies – N8-GP and N9-GP
4.6.6 Bayer: Markets Kogenate, Kogenate FS, and has Submitted BAY 81-8973 for FDA Approval
4.6.7 Limited Opportunities for Biosimilar Challenge
4.6.8 Plasma and Recombinant Coagulating Factors Submarket Forecast, 2015-2025
4.7 Interferons
4.7.1 Interferons: Key Antiviral and MS Therapies Since the 1990s
4.7.2 Leading Interferon Brands in 2014
4.7.3 Interferons for Treating Hepatitis: Its Influence is Decreasing
4.7.4 Competition from Oral Protease and Polymerase Inhibitors
4.7.4.1 Oral Therapies are Expensive
4.7.5 Competition in the MS Therapy Market – Further Challenges for Interferons
4.7.6 Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations
4.7.7 Biogen Launches Pegylated Form of Drug
4.7.8 Interferon Submarket Forecast, 2015-2025
4.8 Enzyme Replacement and Other Protein Therapies Submarket
4.8.1 Cerezyme: Genzyme’s Leading Enzyme Replacement Therapy
4.8.2 Myozyme and Lumizyme
4.8.3 Fabrazyme and Aldurazyme
4.8.4 Botulinum Toxin Brands Include Botox, Dysport and Xeomin
4.8.5 Other Protein Therapeutics Pipeline
4.8.5.1 Athera Buys Sollpura from Eli Lilly and Has Initiated Phase 3 Trials
4.8.5.2 Multikine (CEL-SCI)
4.8.5.3 Vonapantiase (Proteon Therapeutics)
4.8.6 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast, 2015-2025

5. Monoclonal Antibodies Submarket, 2015-2025
5.1 Monoclonal Antibodies Submarket: Scientific and Historical Background
5.1.1 Natural Antibodies: Key to the Immune System
5.1.2 From Serum Therapy to Monoclonal Antibodies
5.1.3 Humanising the mAb
5.1.4 MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases – Great Potential for the Future
5.1.5 MAbs for All? Technologies Come Off Patent
5.2 Five out of the Top-Ten Best-Selling Pharmaceuticals are mAbs
5.3 Autoimmune mAbs
5.3.1 Past Approvals
5.3.2 Humira (AbbVie) – The World’s Best-Selling Prescription Drug
5.3.2.1 AbbVie Plans to Drive Growth Through New Indications and Sales in Emerging Markets
5.3.2.2 Humira Undergoing Phase 3 Trials for Treatment of Uveitis, and Positive Opinion from EMA for Hidradenitis Suppurativa
5.3.2.3 Biosimilar Adalimumab: Patents Protect Humira in Developed Markets but Pipeline is Strong
5.3.3 Remicade (J&J / Merck): Second Only to Humira
5.3.3.1 Biosimilar Infliximab: Inflectra / Remsima Launched in Europe
5.3.4 Simponi: J&J’s Update to Remicade
5.3.5 Stelara (J&J): Reaches Double Blockbuster Status
5.3.6 Tysabri: Biogen Purchases Remaining Rights from Partner to Gain Full Control of Blockbuster Drug
5.3.7 Other Leading Autoimmune mAbs include Xolair, Actemra and Others
5.3.7.1 Leading Companies in the Autoimmune mAbs Sector
5.3.8 Autoimmune mAbs Pipeline: RA is the Main Target
5.3.8.1 Sarilumab (REGN88 / SAR153191) by Regeneron and Sanofi: Likely to be Submitted for Approval This Year
5.3.8.2 Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World
5.3.8.3 Clazakizumab by Alder Biopharmaceuticals: Bristol-Myers Squibb Opts out of Co-Development
5.3.8.4 Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results
5.3.8.5 Mavrilimumab by AstraZeneca: Approaching Phase 3
5.3.8.6 Zinbryta by AbbVie and Biogen: FDA and EMA have Accepted Application, Should be Approved Soon
5.3.8.7 Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results
5.3.8.8 Sifalimumab (MEDI-545) by AstraZeneca: Treatment Targeting SLE
5.4 Oncology mAbs
5.4.1 Past Approvals
5.4.2 Rising Incidence of Cancer will Drive Demand
5.4.3 Rituxan: The World’s Leading Anti-Cancer mAb
5.4.3.1 Biosimilar Rituximab
5.4.4 Gazyva: Roche’s Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition
5.4.4.1 Approval for NHL Could Allow it to Reach its Blockbuster Potential
5.4.5 Avastin: Second in Roche’s Trio of Leading Cancer mAbs
5.4.5.1 Controversy over Off-Label Avastin use
5.4.5.2 Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche
5.4.6 Herceptin: Completes Roche’s Trio of Leading Cancer mAbs
5.4.7 Roche Builds Franchise of Anti-HER2 mAbs around Herceptin with Perjeta and Kadcyla
5.4.8 Challenges for Kadcyla
5.4.9 Perjeta has Already Reached Blockbuster Status
5.4.10 Biosimilar Trastuzumab: Two Biosimilars Already Available and Plenty more in the Pipeline
5.4.11 Yervoy: Bristol-Myers Squibb’s Leading Anti-Cancer mAb Reaches Blockbuster Status
5.4.12 Opdivo: Big Potential for Bristol-Myer Squibb’s PD-1 Inhibitor
5.4.13 Erbitux: Bristol-Myers Squibb Hands Over North American Marketing Responsibilities to Eli Lilly
5.4.14 Oncology mAbs: New Approvals and Pipeline
5.4.14.1 Elotuzumab (Bristol-Myers Squibb and AbbVie): Granted Breakthrough Therapy Designation
5.4.14.2 Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb
5.4.14.3 Unituxin (United Therapeutics) Receives FDA Approval
5.4.14.4 Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014
5.4.14.5 Coltuximab Ravtansine: Sanofi’s Anti-CD19 ADC mAb Candidate
5.5 MAbs in Other Therapeutics Areas
5.5.1 Lucentis (Novartis and Roche): Large Revenues and New Indication, but Also Part of Controversy
5.5.2 Soliris by Alexion Pharmaceuticals
5.5.3 Prolia by Amgen
5.6 Monoclonal Antibodies Submarket Forecast, 2015-2025

6. Fusion Proteins Submarket, 2015-2025
6.1 Scientific and Historical Background
6.2 Differentiating Fusion Proteins
6.3 Enbrel (Amgen / Pfizer): The First FP to be Approved, in 1998
6.3.1 Gradually Approved for Additional Indications
6.3.2 The Leading FP and the Fifth Best-Selling Pharmaceutical Product
6.3.3 Enbrel Granted Extended Patent Protection in the US
6.3.4 However, Biosimilars are Available in Emerging Markets and Patents Due to Expire soon in EU and Japan
6.4 Eylea: Blockbuster FP Treatment for Wet AMD
6.4.1 Approved in Additional Indications in 2014 and 2015
6.4.2 Breakdown of Revenues Between Regeneron and Bayer
6.5 Orencia: Grows Blockbuster Revenues by 14%
6.6 Nplate: Generates Half a Billion in Revenues for Amgen
6.7 Eloctate: Approved Recently in June 2014, Fulfils Unmet Need in the Haemophilia Community
6.8 Nulojix: Bristol-Myers Squibb’s Therapy for Preventing Organ Rejection
6.9 Arcalyst by Regeneron Pharmaceuticals
6.10 Fusion Proteins Pipeline
6.10.1 Merck KGaA Developing Atacicept to Treat SLE
6.10.2 Trebananib (Amgen): Underwhelming Results in One Phase 3 Trial, but Not the End of the Road Yet
6.10.3 Sotatercept by Acceleron Pharma and Celgene Corporation – Currently Undergoing Eight Clinical Trials
6.10.4 Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development
6.11 Fusion Protein Submarket Forecast, 2015-2025

7. Regenerative Medicines Submarket, 2015-2025
7.1 Regenerative Medicines Market Breakdown
7.2 Regenerative Medicines Submarket Forecast, 2015-2025
7.3 Stem Cell Therapies Submarket, 2015-2025
7.3.1 Stem Cells: Scientific Breakdown
7.3.2 Stem Cell Therapies Submarket Breakdown
7.3.3 Haematopoietic Stem Cell Transplantation: Over 80,000 Carried out in 2014
7.3.3.1 From Procedures to Products: Cord Blood Stem Cell Approvals
7.3.4 Osteocel Plus (NuVasive): Has Been Used in over 50,000 Spinal Solid Fusion Cases Worldwide
7.3.4.1 The Road from Osteocel to Osteocel Plus
7.3.5 Trinity Elite and Trinity Evolution (Orthofix): Over 90,000 Procedures to Date
7.3.6 MSC-100-IV / Prochymal by Mesoblast
7.3.6.1 MSC-100-IV’s History and Current Status – Expected US Launch 2017, has already been filed for Approval in Japan
7.3.6.2 Also Being Evaluated for Crohn’s Disease
7.3.7 Cartistem by Medipost – Has Been Used to Treat over 2,000 Patients Thus Far
7.3.8 Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
7.3.9 Stem Cell Therapies Pipeline
7.3.10 Cx601 (TiGenix): European Phase 3 Trial Completed July 2015
7.3.10.1 TiGenix Partners with Lonza, Will Conduct Another Phase 3 Trial in the US
7.3.11 MyoCell (Bioheart): Being Developed for Improvement of Cardiac Functions after Heart Damage
7.3.12 NBS10 (Formerly Known as AMR-001) – NeoStem’s Lead Candidate, Initial Phase 2 Results Promising
7.3.13 NSI-566 (Neuralstem) First Phase 2 Trial Demonstrates Promising Results, a Larger Phase 2 Trial is Planned 2015
7.3.14 Stem Cell Therapies Submarket Forecast, 2015-2025
7.4 Tissue Engineering Therapies Submarket, 2015-2025
7.4.1 What is Tissue Engineering? History and Science
7.4.1.1 Current Market Status
7.4.2 Apligraf by Organogenesis: The Leading Product
7.4.3 Dermagraft: Organogenesis Acquires Product from Shire in 2014
7.4.4 ReCell by Alvita Medical
7.4.5 MySkin and Cryoskin by Regenerys
7.4.6 Tissue Engineering Therapies Pipeline
7.4.6.1 NeoCart by Histogenics is Undergoing Phase 3 Trial for Knee Cartilage Repair
7.4.6.2 Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies: Undergoing Two Phase 3 Clinical Trials
7.4.6.3 StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results
7.4.7 Tissue Engineering Therapies Submarket Forecast, 2015-2025
7.5 Gene Therapies Submarket, 2015-2025
7.5.1 Gene Therapy: Historical and Scientific Background
7.5.1.1 The Role of Viruses Within Gene Therapy
7.5.2 Approved Gene Therapy Products
7.5.2.1 Genidicine (Benda Pharmaceuticals): World’s First Commercial Gene Therapy
7.5.2.2 Oncorine by Shanghai Sunway Biotech
7.5.2.3 Neovasculgen (Human Stem Cells Institute): Russia’s First Gene Therapy
7.5.2.4 Glybera (UniQure): The First Gene Therapy for Western Markets
7.5.3 Gene Therapies Pipeline
7.5.3.1 AAV2-hRPE65v2 (Spark Therapeutics)
7.5.3.2 AdV-tk / ProstAtak (Advantagene)
7.5.3.3 T-Vec (Amgen)
7.5.4 Gene Therapies Submarket Forecast, 2015-2025

8. Leading National Markets for Biologics, 2015-2025
8.1 Composition of the Market in 2014 and 2025: US Will Remain Dominant
8.2 Regional Forecasts for the Global Biologics Market, 2015-2025
8.3 US Biologics Market, 2015-2025
8.3.1 The Major National Market
8.3.2 Value-Based Pricing in the US
8.3.3 Regulation of Biologics in the US
8.3.4 US Biosimilar Market
8.3.4.1 FDA Finalises Biosimilar Guidelines
8.3.5 US Biologics Market Forecast, 2015-2025
8.4 EU5 Biologics Market, 2015-2025
8.4.1 Current Composition and Future Outlook
8.4.2 European Biosimilars Market
8.4.2.1 EMA Biosimilar Guidelines and Updates 2012-2014
8.4.3 EU5 Market Forecast by Nation, 2015-2025
8.5 Japanese Biologics Market, 2015-2025
8.5.1 Current Status of the Japanese Biologics Market
8.5.2 Japanese Biosimilars Market
8.5.3 Japanese Biologics Market Forecast, 2015-2025
8.6 BRIC National Biologic Markets, 2015-2025
8.6.1 BRIC Markets Overview
8.6.2 BRIC Biologic Market Forecast, 2015-2025
8.6.2.1 Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market
8.6.2.2 Future Outlook
8.6.2.3 BRIC Nation Market Shares in the Global Biologics Market will Nearly Double During the Forecast Period
8.6.3 Brazil: Disproportionately High Government Spending on Biologics
8.6.3.1 Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development
8.6.4 Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development
8.6.5 India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving
8.6.5.1 CDSCO Guidelines Released in 2012
8.6.6 China: Expected to the Largest BRIC Market for Biologics by 2019
8.6.6.1 The Largest National Biosimilar Market in the World

9. Qualitative Analysis of the Biologics Market and Industry
9.1 SWOT Analysis of the Global Biologics Market and Industry
9.1.1 Strengths
9.1.2 Opportunities
9.1.3 Weaknesses
9.1.4 Threats
9.2 STEP Analysis of the Global Biologics Market and Industry
9.2.1 Social Factors
9.2.2 Technological Developments
9.2.3 Economic Pressures
9.2.4 Political Issues

10. Conclusions from the Research and Analysis
10.1 Biologics Market to Achieve Steady Growth Through the Forecast Period
10.2 Changes in Market Composition: mAbs to Become Leading Submarket
10.3 The Emergence of Biosimilars
10.4 Challenges for the Market

List of Tables
Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 3.1 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2014-2019
Table 3.2 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.3 Top Ten Best-Selling Drugs of 2014: Revenues ($bn), Market Shares (%)
Table 3.4 Patent Status of the Seven Top Biologics within the Overall Biologics Market, 2015
Table 3.5 Biologics - Submarket Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2014-2019
Table 3.6 Biologics - Submarket Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 4.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 4.2 Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), 2014-2019
Table 4.3 Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 4.4 Diabetes Prevalence in Leading National Markets, 2014
Table 4.5 Types of Injectable Insulin, 2015
Table 4.6 Selected Insulin Biosimilars which have been Approved
Table 4.7 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.8 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 4.9 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.10 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 4.11 Selected Coagulating Factors Significant in Segment
Table 4.12 Plasma and Recombinant Coagulating Factors Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.13 Plasma and Recombinant Coagulating Factors Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 4.14 Selected Approved Branded Interferon Therapies
Table 4.15 Interferon Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.16 Interferon Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 4.17 Enzyme Replacement and Other Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.18 Enzyme Replacement and Other Protein Therapeutics Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 5.1 Regions of an Antibody
Table 5.2 Natural Antibody Mechanisms of Action
Table 5.3 Top Five Best-Selling mAbs, 2014
Table 5.4 Selected Leading Autoimmune mAbs: Revenue ($bn), 2014
Table 5.5 Breakdown of Erbitux Revenues between Merck KGaA, Bristol-Myers Squibb and Eli Lilly: Revenue ($bn), Percentage Change (%), Percentage of 2014 Revenues (%), 2013 and 2014
Table 5.6 mAbs Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 5.7 mAbs Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.1 Amgen’s US Patents and Expiry Dates for Enbrel
Table 6.2 Breakdown of Eylea’s Revenues between Regeneron and Bayer, 2014 and 2013: Revenue ($bn), Percentage Change (%), Percentage of Profits (%), 2014
Table 6.3 Fusion Proteins Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 6.4 Fusion Proteins Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 7.1 Regenerative Medicines Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 7.2 Regenerative Medicines Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 7.3 Potency and Source of Stem Cells
Table 7.4 Stem Cell Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 7.5 Stem Cell Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 7.6 Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 7.7 Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 7.8 Gene Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 7.9 Gene Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 8.1 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 8.2 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 8.3 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 8.4 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 8.5 European Biosimilar Approvals, 2006-2014
Table 8.6 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 8.7 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 8.8 Biosimilars Approved in Japan, 2015
Table 8.9 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 8.10 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 8.11 BRIC Biologics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 8.12 BRIC Biologics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025

List of Figures
Figure 1.1 Therapeutic Technologies and Segments of the Biologics Market, 2015
Figure 3.1 Global Biologics Market Forecast: Revenues ($bn), 2014-2025
Figure 3.2 Market Shares ($bn, %) of the Seven Top Biologics within the Overall Biologics Market, 2014
Figure 3.3 Biologics Market - Submarket Forecasts: Revenues ($bn), 2014-2025
Figure 4.1 Protein Therapeutics Submarket: Revenues ($bn), 2014-2025
Figure 4.2 Diabetes Prevalence in Leading National Markets, 2014
Figure 4.3 Insulin Submarket Forecast: Revenues ($bn), 2014-2025
Figure 4.4 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), 2014-2025
Figure 4.5 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), 2014-2025
Figure 4.6 Interferons Submarket Forecast: Revenues ($bn), 2014-2025
Figure 4.7 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), 2014-2025
Figure 5.1 mAbs Submarket Forecast: Revenues ($bn), 2014-2025
Figure 6.1 Fusion Protein Submarket Forecast: Revenues ($bn), 2014-2025
Figure 7.1 Regenerative Medicines Submarket Forecast: Revenues ($bn), 2014-2025
Figure 7.2 Stem Cell Therapies Submarket Forecast: Revenues ($bn), 2014-2025
Figure 7.3 Tissue Engineering Therapies Submarket Forecast: Revenues ($bn), 2014-2025
Figure 7.4 Gene Therapies Submarket Forecast: Revenues ($bn), 2014-2025
Figure 8.1 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2014
Figure 8.2 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2025
Figure 8.3 Regional Forecasts for Global Biologics Market: Revenues ($bn), 2014-2025
Figure 8.4 US Biologics Market Forecast: Revenues ($bn), 2014-2025
Figure 8.5 EU5 Market Breakdown: Market Share (%), 2014
Figure 8.6 Germany, France, UK, Italy, Spain: Biologics Market Forecasts, 2014-2025
Figure 8.7 EU5 Combined Biologics Market Forecast, 2014-2025
Figure 8.8 Japanese Biologics Market Forecast, 2014-2025
Figure 8.9 BRIC Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2014
Figure 8.10 BRIC Biologics Market Forecasts, 2014-2025
Figure 8.11 BRIC Combined Market Forecast, 2014-2025
Figure 8.12 BRIC Market Composition: Revenue ($bn), Market Share (%), 2025
Figure 9.1 SWOT Analysis of Biologics Market and Industry, 2015
Figure 9.2 STEP Analysis of Biologics Market and Industry, 2015
Figure 10.1 Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2014-2025
Figure 10.2 Breakdown by Submarket: Revenues ($bn), 2014-2025

【レポートのキーワード】

生物製剤、蛋白質療法、単クローン抗体、融合蛋白、再生医療、ワクチン、バイオ後続品、製薬、医薬品、治療、研究開発

★調査レポート[生物製剤の世界市場:蛋白質療法、単クローン抗体、融合蛋白、再生医療、ワクチン] ( Global Biologics Market, Industry and R&D: Forecasts 2015-2025 : Challenges and Opportunities from Rising Drug Demand and Biosimilar Competition / VGAIN5081915) 販売に関する免責事項
[生物製剤の世界市場:蛋白質療法、単クローン抗体、融合蛋白、再生医療、ワクチン] ( Global Biologics Market, Industry and R&D: Forecasts 2015-2025 : Challenges and Opportunities from Rising Drug Demand and Biosimilar Competition / VGAIN5081915) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆